Literature DB >> 25739610

Therapeutic cancer vaccine survives biotech bust.

Heidi Ledford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25739610     DOI： 10.1038/nature.2015.16990

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  1 in total

1.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245
  1 in total
  14 in total

Review 1.  Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.

Authors:  Nicole J Piscopo; Katherine P Mueller; Amritava Das; Peiman Hematti; William L Murphy; Sean P Palecek; Christian M Capitini; Krishanu Saha
Journal:  Biotechnol J       Date:  2017-09-18       Impact factor: 4.677

2.  Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.

Authors:  Motao Zhu; Xilai Ding; Ruifang Zhao; Xuewu Liu; Haifa Shen; Chunmei Cai; Mauro Ferrari; Helen Y Wang; Rong-Fu Wang
Journal:  J Control Release       Date:  2018-01-08       Impact factor: 9.776

Review 3.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.

Authors:  Xiaopin Duan; Christina Chan; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-15       Impact factor: 15.336

4.  Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy.

Authors:  Qian Chen; Ligeng Xu; Chao Liang; Chao Wang; Rui Peng; Zhuang Liu
Journal:  Nat Commun       Date:  2016-10-21       Impact factor: 14.919

5.  A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.

Authors:  Yasuki Hijikata; Toshihiko Okazaki; Yoshihiro Tanaka; Mutsunori Murahashi; Yuichi Yamada; Kazunari Yamada; Atsushi Takahashi; Hiroyuki Inoue; Junji Kishimoto; Yoichi Nakanishi; Yoshinao Oda; Yusuke Nakamura; Kenzaburo Tani
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

Review 6.  Recent Advances in Prostate Cancer Treatment and Drug Discovery.

Authors:  Ekaterina Nevedomskaya; Simon J Baumgart; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

7.  Ganoderma Lucidum Polysaccharides Enhance the Abscopal Effect of Photothermal Therapy in Hepatoma-Bearing Mice Through Immunomodulatory, Anti-Proliferative, Pro-Apoptotic and Anti-Angiogenic.

Authors:  Qing-Hai Xia; Cui-Tao Lu; Meng-Qi Tong; Meng Yue; Rui Chen; De-Li Zhuge; Qing Yao; He-Lin Xu; Ying-Zheng Zhao
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

8.  Challenges in the translation and commercialization of cell therapies.

Authors:  Brittany P Dodson; Aaron D Levine
Journal:  BMC Biotechnol       Date:  2015-08-07       Impact factor: 2.563

Review 9.  The Promise of Preventive Cancer Vaccines.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Elena Quaglino
Journal:  Vaccines (Basel)       Date:  2015-06-17

10.  A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.

Authors:  María Alejandra Gleisner; Cristián Pereda; Andrés Tittarelli; Mariela Navarrete; Camila Fuentes; Ignacio Ávalos; Fabian Tempio; Juan Pablo Araya; María Inés Becker; Fermín Eduardo González; Mercedes Natalia López; Flavio Salazar-Onfray
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.